未登录

P

Pangke Yan

Haisco Pharmaceutical Group Co. Ltd

H指数:11

被引数:640

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effects of Cipepofol on Cardiac Depolarization and Repolarization in Healthy Subjects: A Single-Center; Randomized; Placebo and Positive-Controlled Thorough QT Study

西佩波酚对健康受试者心脏除极和复极的影响：一项单中心、随机、安慰剂和阳性对照的详尽QT研究

drug design; development and therapy

IF0

2026-01-140

OAAI

Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, phase 3 trial

cofrogliptin每2周一次在中国2型糖尿病患者中的疗效和安全性: 一项随机，双盲，安慰剂对照的3期试验

DIABETES OBESITY & METABOLISM

IF5.7

2024-10-210

PRE

Model informed drug development: HSK21542 PBPK model supporting dose decisions in specific populations

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

IF4.7

2024-05-011

OA

Potent and orally bioavailable BCL6 protein degraders demonstrate efficacy in pre-clinical models of diffuse large B-cell lymphoma (DLBCL)

CANCER RESEARCH

IF16.6

2024-03-220

PRE

HSK41959-2: An oral MTA-cooperative PRMT5 inhibitor for MTAP deleted cancer

CANCER RESEARCH

IF16.6

2024-03-220

PRE

HSK42360: A potent, brain permeable, BRAF paradox breaker for the treatment of BRAF-driven cancers

CANCER RESEARCH

IF16.6

2024-03-220

PRE

HSK40495, a highly selective PARP1 inhibitor with improved hematopoietic safety for the treatment of HRD cancers

CANCER RESEARCH

IF16.6

2024-03-221

PRE

HSK39775: A USP1 inhibitor for the treatment of cancers with homologous recombination deficiencies

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Pharmacokinetics and exposure-safety relationship of ciprofol for sedation in mechanically ventilated patients in the intensive care unit

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-03-053

OA

Population pharmacokinetic/pharmacodynamic modeling and exposure-response analysis of ciprofol in the induction and maintenance of general anesthesia in patients undergoing elective surgery: A prospective dose optimization study

JOURNAL OF CLINICAL ANESTHESIA

IF5.1

2024-02-0112

PRE

Comparison of the Efficacy of HSK3486 and Propofol for Induction of General Anesthesia in Adults: A Multicenter, Randomized, Double-blind, Controlled, Phase 3 Noninferiority Trial

IF9.1

2023-12-279

OA

Dose decision of HSK7653 oral immediate release tablets in specific populations clinical trials based on mechanistic physiologically-based pharmacokinetic model

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

IF4.7

2023-10-014

OA

Phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in patients with relapsed or refractory B-cell malignancies

CANCER RESEARCH

IF16.6

2023-04-1410

PRE

HSK38008: An oral AR-V7 degrader for metastatic castration-resistant prostate cancer

CANCER RESEARCH

IF16.6

2023-04-140

PRE

Population total and unbound pharmacokinetics and pharmacodynamics of ciprofol and M4 in subjects with various renal functions

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2022-11-049

PRE

Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment

ANNALS OF MEDICINE

IF4.3

2022-10-1012

OAAI

Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2020-08-0396

OAAI

Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2020-05-2632

PREAI

Oral Delivery of Propofol with Methoxymethylphosphonic Acid as the Delivery Vehicle

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2017-10-1247

PREAI

SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models

ACTA PHARMACOLOGICA SINICA

IF8.4

2014-05-0216

OAAI